Randy Ackerman,  MD

• Incontinence (Female and Male)
• Pelvic Floor Dysfunction
• Prolapse
• Cystocele
• Rectocele
• Erectile Dysfunction (Impotence)
• Hypogandism (Low Testosterone)
• Bladder Cancer
• Kidney Cancer
• Prostate Cancer
• Testicular Cancer
• Kidney Stones

• Virtua (Marlton, Voorhees)
• Our Lady of Lourdes (Camden)
• Inspira Medical Center (Elmer, Vineland, Woodbury)

• American Urological Association
• Camden County Medical Society
• Pennsylvania Medical Society
• Mid Atlantic Urologic Association

Scientific Papers:

• “Comparison Of Complications Of Radical Retropubic Versus Radical Perineal Prostatectomy”, presented at ACOS Meeting in New Orleans, Louisiana, September 1995
• “A Retrospective Analysis of Renal Trauma At A Level 1 Trauma Center”, presented at Ferdinand Valentine Essay Contest, April 1991, New York, NY
  Drug investigations: A Phase III efficacy and safety study of three fixed doses of Apomorphine SL Tablets versus placebo in the treatment of male Erectile Dysfunction. (m96-470)
• A Phase III long-term, open label, flexible dose, efficacy and safety study of Apomorphine SL Tablets in the treatment of male Erectile Dysfunction. (M96-471)
• A Phase III Efficacy and safety study of four fixed doses of Apomorphine SL Tablets versus placebo in the treatment of male Erectile Dysfunction. (M96-658)
• A Phase III long-term, open label, flexible dose, efficacy and safety study of Apomorphine SL Tablets in the treatment of male Erectile Dysfunction for TAP Holdings, Inc. (M97-659)
• A Phase III long-term, open label, flexible dose, safety extension study of Apomorphine SL Tablets in the treatment of male Erectile Dysfunction for TAP Holdings, Inc. (M97-682)
• A Phase III Efficacy and Safety Study Comparing Escalating Doses of Apomorphine SL to 5 mg or 6 mg Doses of Amorphine SL or placebo in the treatment of Male Erectile Dysfunction. (M97-763)
• A Phase III efficacy and safety study of three fixed doses of Apomorphine SL Tablets 2,4, and 5 mg versus placebo in the treatment of Male Erectile Dysfunction for Tap Holdings, Inc. (M98-941)
• A Phase III, two year, long-term, open-label, flexible dose, safety extension study of Apomorphine SL Tablets in the treatment of Male Erectile Dysfunction for Tap Holdings, Inc. (M98-936)

Co-investigator:

• A study to evaluate the impact of Viagra on treatment satisfaction for Pfizer, Inc. (R-1529)
• Long-term effects on Finasteride in patients with benign prostatic hyperplasia for Merck Sharp & Dohme research laboratories and FDA. (MK-906)
• A study to evaluate the effectiveness of circulating PSA as measured by the TOSOH Medics, Inc. AIA Pack Assay as an aid in early detection and diagnosis of Prostate Cancer. Diagnostic Oncology, CRO Inc.
• An eleven-week, open label, randomized, multicenter, parallel-design, placebo lead-in study of Flomax Capsules, 0.4 mg daily versus Hytrin Capsules, 5 mg (with Tirtation) daily in patients with the signs and symptoms of Benign Prostatic Hyperplasia for Boehringer Ingelheim Pharmaceuticals, Inc (527-17)

Always check with your health insurance carrier before scheduling any type of service. You can learn the details of your individual health insurance plan, including the amount of your copay, deductible, and coinsurance by visiting your health insurance company’s website or by calling their customer service department.

View Accepted Insurance Plans